We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03655613
Recruitment Status : Terminated (Study terminated due to administrative reasons.)
First Posted : August 31, 2018
Last Update Posted : May 6, 2022
Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.)
Novotech (Australia) Pty Limited
Information provided by (Responsible Party):
Apollomics (Australia) Pty. Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : December 15, 2021
Actual Study Completion Date : December 15, 2021